IntegraGen appoints Bernard Courtieu as CEO in a move to accelerate its commercial efforts

Paris, France and New York, USA - 17 September 2007 - IntegraGen SA, a personalized healthcare company focused on the development and commercialization of molecular diagnostic tests for complex diseases, has announced the appointment of Dr. Bernard Courtieu as Chief Executive Officer.

Dr. Courtieu has over 15 years’ experience in the healthcare and pharmaceutical industry, where he became Vice President and Practice Leader for the Life Sciences division of Gemini Consulting in France. His tenure with Eurostart, Bossard Gemini Consulting and Cap Gemini Ernst & Young yielded hands-on experience in improving the operational performance of pharmaceutical companies in the fields of Research and Development, Industrial Operations, Supply Chain, Sales & Marketing and Information Systems. Adding to his commercial experience, Dr. Courtieu spent the past three years at Ariba as Country Manager for France, and Head of Implementation in Europe. Dr. Courtieu holds an MBA from the Instituto de las Estudios Superiores de la Empresa (IESE) in Barcelona, Spain and received his doctorate in Veterinary Medicine from the Ecole Vétérinaire d'Alfort and University Paris XII, France.

Commenting on his appointment, Dr. Courtieu said: “I am excited to join IntegraGen at this pivotal point in the Company’s development. The foundation is strong. We are on the brink of emerging from a research and services firm with an impressive track record, to a company able to quickly deliver innovative products though our pipeline and fuel further discovery. Our focus on diseases such as obesity, autism, diabetes, schizophrenia and bipolar disorder are in-line with the needs of clinicians, patients, and our network of partners.”

Gerard Vaillant, member of the Board, added: “We are delighted to welcome Dr. Courtieu as CEO. IntegraGen has enjoyed great success over the past six years, leveraging both its proprietary technology GenomeHIP, and expanding its analytical and biostatistical team. Dr. Courtieu’s skill set is suited to accelerate and focus our commercial efforts, which will facilitate further development of the Company. With a rapidly growing portfolio of markers, and an expanding services business, IntegraGen is quickly moving from a primary research organization to a fully integrated molecular diagnostics company.”

IntegraGen recently established IntegraGen, Inc., a wholly-owned U.S. subsidiary based in New York, to commercialize its molecular tests in the U.S.A. The Company also operates an ISO accredited Molecular Diagnostics Center in Germany that offers genetic testing services for diabetes.

- ENDS -

Notes to editors:

About IntegraGen

IntegraGen is a pioneer in the field of predictive healthcare. The company uses its unique capabilities to identify genes associated with complex diseases and commercializes molecular diagnostic tests to enable individualized diagnosis, prevention and treatment.

IntegraGen’s proprietary gene mapping technology GenomeHIP provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Efforts are currently focused on Type-2 Diabetes, Obesity, Autism and Bi-Polar Disorder. Clinical trials for the company’s first genetic test for autism are ongoing.

Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, in Bonn, Germany and in New York, USA. More information can be found at www.integragen.com.

For further information please contact:

Northbank Communications
Sue Charles, Christelle Kerouedan, Katie Odgaard, Tony Stephenson
Tel: +44 (0)20 7268 3002
E-mail: integragen@northbankcommunications.com